Literature DB >> 27278135

Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension.

Thomas Weber1, Irene Lang2, Robert Zweiker3, Sabine Horn4, Rene R Wenzel5, Bruno Watschinger6, Jörg Slany7, Bernd Eber8, Franz Xaver Roithinger9,10, Bernhard Metzler11.   

Abstract

High blood pressure is a major modifiable risk factor for all clinical manifestations of coronary artery disease (CAD). In people without known cardiovascular disease, the lowest systolic (down to 90-114 mmHg) and the lowest diastolic (down to 60-74 mmHg) pressures are associated with the lowest risk for developing CAD. Although diastolic blood pressure is the strongest predictor of CAD in younger and middle-aged people, this relationship becomes inverted and pulse pressure shows the strongest direct relationship with CAD in people above 60 years of age.Pathophysiological mechanisms of blood pressure as a risk factor for CAD are complex and include the influence of blood pressure as a physical force on the development of the atherosclerotic plaque, and the relationship between pulsatile hemodynamics/arterial stiffness and coronary perfusion. Treatment of arterial hypertension has been proven to prevent coronary events in patients without clinical CAD. In patients with established CAD, the effect of blood pressure lowering per se is beneficial, probably more than specific drugs or drug classes. The important exceptions are beta blockers (BBs), which are superior to all other drug classes for use after a recent myocardial infarction. Blood pressure targets in patients with established CAD have created controversy in the light of the so-called J-curve phenomenon, which describes an increase in coronary events at lower diastolic blood pressures. One explanation for this observation is that perfusion of the left ventricle occurs predominantly during diastole, and that coronary autoregulation may be exhausted with low diastolic blood pressure in the setting of left ventricular hypertrophy and atherosclerotic narrowing of the epicardial coronaries. The worst situation is a high systolic blood pressure in the presence of a low diastolic blood pressure, both a hallmark of increased aortic stiffness. However, the lowering of systolic blood pressure is clearly beneficial in this setting, even at the price of further lowering diastolic pressure. Primary blood pressure goal in patients with established CAD is below 140/90 mmHg. Recent studies suggest that a lower systolic blood pressure may be appropriate, whereas caution is advised with diastolic blood pressure below 60 mmHg.

Entities:  

Keywords:  Arterial hypertension; Arterial stiffness; Blood pressure goals; Coronary artery disease; J‑curve

Mesh:

Substances:

Year:  2016        PMID: 27278135     DOI: 10.1007/s00508-016-0998-5

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  82 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Does coronary flow trump coronary anatomy?

Authors:  K Lance Gould
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

Review 3.  Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.

Authors:  Costas Thomopoulos; Gianfranco Parati; Alberto Zanchetti
Journal:  J Hypertens       Date:  2015-07       Impact factor: 4.844

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

6.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

7.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

8.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

Review 9.  Mechanical factors in arterial aging: a clinical perspective.

Authors:  Michael F O'Rourke; Junichiro Hashimoto
Journal:  J Am Coll Cardiol       Date:  2007-06-18       Impact factor: 24.094

10.  Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial.

Authors:  Martin G Myers; Marshall Godwin; Martin Dawes; Alexander Kiss; Sheldon W Tobe; F Curry Grant; Janusz Kaczorowski
Journal:  BMJ       Date:  2011-02-07
View more
  9 in total

1.  Assessment of decellularized pericardial extracellular matrix and poly(propylene fumarate) biohybrid for small-diameter vascular graft applications.

Authors:  Megan Kimicata; Jules D Allbritton-King; Javier Navarro; Marco Santoro; Takahiro Inoue; Narutoshi Hibino; John P Fisher
Journal:  Acta Biomater       Date:  2020-04-16       Impact factor: 8.947

2.  Identification of molecular mechanisms underlying the therapeutic effects of Xintong granule in coronary artery disease by a network pharmacology and molecular docking approach.

Authors:  Zhihong Huang; Siyu Guo; Changgeng Fu; Wei Zhou; Antony Stalin; Jingyuan Zhang; Xinkui Liu; Shanshan Jia; Chao Wu; Shan Lu; Bingbing Li; Zhishan Wu; Yingying Tan; Xiaotian Fan; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

Review 3.  The Role of Arterial Stiffness and Central Hemodynamics in Heart Failure.

Authors:  Thomas Weber
Journal:  Int J Heart Fail       Date:  2020-09-23

4.  Evaluation of periostin levels in gingival crevicular fluid in association between coronary heart disease and chronic periodontitis.

Authors:  Babak Rezaei; Mojtaba Bayani; Mehdi Anvari; Pedram Vahed
Journal:  Dent Res J (Isfahan)       Date:  2021-06-22

5.  Inter-arm blood pressure difference as a tool for predicting coronary artery disease severity.

Authors:  Somen Das; Mohammad Azmain Iktidar; Joyanti Das; Faisal Chowdhury; Simanta Roy
Journal:  Open Heart       Date:  2022-08

6.  Patients with comorbid coronary artery disease and hypertension: a cross-sectional study with data from the NHANES.

Authors:  Yu Chen; Zhen-Fa Zhou; Ji-Ming Han; Xian Jin; Zhi-Feng Dong; Liang Liu; Di Wang; Tian-Bao Ye; Bo-Shen Yang; Ya-Ping Zhang; Cheng-Xing Shen
Journal:  Ann Transl Med       Date:  2022-07

Review 7.  Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting-Beyond Platelet Inhibition.

Authors:  Dominika Siwik; Magdalena Gajewska; Katarzyna Karoń; Kinga Pluta; Mateusz Wondołkowski; Radosław Wilimski; Łukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

8.  Effects of data preprocessing on results of the epidemiological analysis of coronary heart disease and behaviour-related risk factors.

Authors:  Ari Voutilainen; Christina Brester; Mikko Kolehmainen; Tomi-Pekka Tuomainen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 9.  A Novel Promising Frontier for Human Health: The Beneficial Effects of Nutraceuticals in Cardiovascular Diseases.

Authors:  Albino Carrizzo; Carmine Izzo; Maurizio Forte; Eduardo Sommella; Paola Di Pietro; Eleonora Venturini; Michele Ciccarelli; Gennaro Galasso; Speranza Rubattu; Petro Campiglia; Sebastiano Sciarretta; Giacomo Frati; Carmine Vecchione
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.